Analyst Price Target is $8.50
▲ +2,025.00% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Agile Therapeutics in the last 3 months. The average price target is $8.50, with a high forecast of $12.00 and a low forecast of $5.00. The average price target represents a 2,025.00% upside from the last price of $0.40.
Current Consensus is
Moderate Buy
The current consensus among 2 polled investment analysts is to moderate buy stock in Agile Therapeutics. This Moderate Buy consensus rating has held steady for over two years.
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.
Read More
